Quality Quartets in Risk-Based Qualification

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, May 2023
Volume 47
Issue 5
Pages: 53-57

Quality Quartet Registers connect Quality Quartets to their process system or unit operation “parent.”

ANDRANIK123 - STOCK.ADOBE.COM

ANDRANIK123 - STOCK.ADOBE.COM

The Quality Quartet is a proposed technical mechanism to eliminate inconsistencies and deficiencies within and between the commissioning and qualification (C&Q) and process validation (PV) lifecycles. Quality Quartets are four-component objects comprising two process and two system parts, but itemized and managed as singularities. Using a combination of International Council for Harmonisation (ICH) and International Society of Pharmaceutical Engineering (ISPE) terminology, the process parts are critical quality attribute (CQA) and critical process parameter (CPP), and the related system parts are critical aspect (CA) and critical design element (CDE). When implemented, Quality Quartets clearly demonstrate 100% connectivity between C&Q and PV datasets. They also facilitate unambiguous communication between product development and facility delivery silos, and between manufacturers and regulators.

ISPE re-issued its C&Q Baseline Guide in 2019 to take account of the global regulatory expectation for patient-centric, risk-based design and delivery of manufacturing processes and systems. The guide now runs to more than 200 pages, including appendices (1).

This paper explains the essential aspects of the guide. The guide is summarized by annotating its underlying principles and recommended workflow. Several practical recommendations are included targeted at optimizing implementation of the guide. Advantages of grouping CQAs, CPPs, CAs, and CDEs into Quality Quartets are discussed.

Click here for a PDF of this article.

About the author

Cliff Campbell is senior consultant at KPC.

Article details

Pharmaceutical Technology
Vol. 47, No. 5
May 2023
Page: 53-57

Citation

When referring to this article, please cite it as Campbell, C. Quality Quartets in Risk-Based Qualification. Pharmaceutical Technology 2023 47 (5).

Recent Videos
Drug Digest: Strategic Partnerships
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content